Effects of two different dosing regimens of terlipressin on organ functions in ovine endotoxemia

Inflammation Research

Volumn 60, Issue 5, 2011, Pages 429-437

  Lange, Matthias ^a   Ertmer, Christian ^a   Rehberg, Sebastian ^a   Morelli, Andrea ^b   Köhler, Gabriele ^a   Kampmeier, Tim G ^a   Van Aken, Hugo ^a   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Arginine vasopressin; Sepsis; Sheep; Vascular leakage

Indexed keywords

ARGIPRESSIN; HAEMOPRESSIN; PLASMA PROTEIN; TERLIPRESSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BOLUS INJECTION; CAPILLARY LEAK SYNDROME; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; ENDOTOXEMIA; FEMALE; HEART FUNCTION; HISTOPATHOLOGY; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN BLOOD LEVEL; SHEEP;

ANIMALS; BLOOD PROTEINS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; ENDOTOXINS; FEMALE; HEMODYNAMICS; INFLAMMATION; LYPRESSIN; PERMEABILITY; RANDOM ALLOCATION; SALMONELLA TYPHI; SHEEP; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 79955933569     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-010-0299-9     Document Type: Article

References (32)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10. (Pubitemid 32641789)
2. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588-95.
3. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrineresistant septic shock. Lancet. 2002;359:1209-10.
4. Albanese J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005;33:1897-902. (Pubitemid 41306507)
5. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. Shock. 2004;22:314-9. (Pubitemid 39468969)
6. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2001:CD002147.
7. Medel J, Boccara G, Van de Steen E, Bertrand M, Godet G, Coriat P. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth Analg. 2001;93:53-5.
8. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med. 2004;30:597-604. (Pubitemid 38530094)
9. Scharte M, Meyer J, Van Aken H, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med. 2001;29: 1756-60. (Pubitemid 32848377)
10. Asfar P, Hauser B, Ivanyi Z, Ehrmann U, Kick J, Albicini M, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med. 2005;33: 373-80. (Pubitemid 40216552)
11. Morelli A, Ertmer C, Lange M, Westphal M. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better? Intensive Care Med. 2007;33:1669-70.
12. Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock. 2007;28:623-9. (Pubitemid 350287450)
13. Westphal M, Sielenkamper AW, Van Aken H, Stubbe HD, Daudel F, Schepers R, et al. Dopexamine reverses the vasopressin- associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia. Anesth Analg. 2004;99:878-85. (Pubitemid 39100383)
14. Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, et al. Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med. 2003;31:1502-8. (Pubitemid 36583866)
15. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340-8. (Pubitemid 38950593)
16. Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock. 2007;27:281-8.
17. Rehberg S, Ertmer C, Kohler G, Spiegel HU, Morelli A, Lange M, et al. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med. 2009;35:1286-96.
18. Petersen MB. The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease. Basic Clin Pharmacol Toxicol. 2006;99:96-103. (Pubitemid 44213937)
19. Bernadich C, Bandi JC, Melin P, Bosch J. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology. 1998;27:351-6. (Pubitemid 28081046)
20. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res. 1990;16:307-14.
21. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009;13:R130.
22. Ouattara A, Landi M, Le Manach Y, Lecomte P, Leguen M, Boccara G, et al. Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart. Anesthesiology. 2005;102:85-92. (Pubitemid 40082844)
23. Evora PR, Pearson PJ, Rodrigues AJ, Viaro F, Schaff HV. Effect of arginine vasopressin on the canine epicardial coronary artery: experiments on V1-receptor-mediated production of nitric oxide. Arq Bras Cardiol. 2003;80:483-94.
24. Dunser MW, Mayr AJ, Stallinger A, Ulmer H, Ritsch N, Knotzer H, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med. 2002;28:746-51. (Pubitemid 34639488)
25. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313-9. (Pubitemid 36578501)
26. Duenser MW, Hasibeder WR. Dear vasopressin, where is your place in septic shock? Crit Care. 2005;9:134-5.
27. Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005;33:2659-66. (Pubitemid 41682122)
28. Farand P, Hamel M, Lauzier F, Plante GE, Lesur O. Review article: organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis. Can J Anaesth. 2006;53:934-46. (Pubitemid 44710260)
29. Schuller D, Mitchell JP, Calandrino FS, Schuster DP. Fluid balance during pulmonary edema. Is fluid gain a marker or a cause of poor outcome? Chest. 1991;100:1068-75.
30. Laporte R, Wisniewska H, Callejas L, Russell J, Landry D, Rivière P. The selective V1a receptor agonist FE202158 reverses platelet activated factor (PAF)-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats. Shock. 2008;Suppl 1(Abstract):P21.
31. Traber D. Selective V1a receptor agonists in experimental septic shock. Crit Care. 2007;11(Abstract):P51.
32. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, et al. Hemodynamic and coagulation responses to 1-desamino[8-Darginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med. 1988;318:881-7. (Pubitemid 18090272)